Adelaide Research & Scholarship
Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/64834
| Type: | Conference paper |
| Title: | Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial |
| Author: | Yeung, D. Osborn, M. White, D. Branford, S. Haswell, L. Slader, C. Issa, S. Hiwase, D. Hertzberg, M. Schwarer, A. Filshie, R. Arthur, C. Kwan, Y. Forsyth, C. Ross, D. Mills, A. Grigg, A. Hughes, T. |
| Citation: | Blood, 2010; 116 (21), Abstract 209 |
| Issue Date: | 2010 |
| Conference Name: | Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.) |
| Organisation: | Australasian Leukaemia & Lymphoma Group |
| Statement of Responsibility: | David T. Yeung, Michael Osborn, Deborah L. White, Susan Branford, Lauren Haswell, Cassandra Slader, Samar Issa, Devendra K. Hiwase, Mark S. Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg and Timothy Hughes and on behalf of ALLG |
| Description: | Oral session ASH Annual Meeting Abstracts: 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010 |
| Rights: | © 2010 American Society of Hematology |
| Description (link): | http://abstracts.hematologylibrary.org/content/vol116/issue21/ |
| Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.